Sarepta Therapeutics, Inc.

SRPTleader

Sarepta Therapeutics is the leader in treatments for Duchenne muscular dystrophy (DMD) — a fatal muscle-wasting disease affecting young boys. Its gene therapy Elevidys is the first approved treatment to address the genetic root cause.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($1.9B)

Data statis (memuat keuangan langsung…)

Elevidys (40%)

Exondys 51 + Other Exon Skipping (60%)

Komposisi segmen dan pelanggan utama

Detail produk

Elevidys (Delandistrogene Moxeparvovec)55%

First FDA-approved gene therapy for Duchenne muscular dystrophy — one-time treatment targeting the root cause.

Exon Skipping Drugs (Exondys/Vyondys/Amondys)45%

Exon 51/53/45 skipping drugs — monthly IV infusions for specific DMD mutations.

Hubungan Rantai Pasok

Mitra

roche

Elevidys co-promotion (Roche/Genentech in ex-US)

Dampak: significant

Konteks makro dan pasar

헬스케어Berita sektor

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Katalis mendatang

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Sarepta Therapeutics, Inc..

Info Perusahaan

Kantor Pusat

Cambridge, MA

Didirikan

1980

Karyawan

1,900

Situs Web

sarepta.com

Gambaran umum sektor — 헬스케어

Berita sektor